Biotech Startups

Stonewise builds an AI-powered small-molecule drug design platform using multimodal 3D molecular generation models for pharmaceutical research and development. The company leverages molecular dynamics simulation and machine learning to assist drug discovery teams in structure analysis and molecular information extraction.

1 investor

aceRNA Technologies develops therapies based on RNA technology, focusing on the discovery of new functions of miRNA to contribute to regenerative medicine and the creation of new drugs for diseases that currently lack treatments. The company operates in the biotech and drug discovery field.

1 investor

Arktus Therapeutics develops regenerative medicine treatments derived from iPS cells, initially focusing on knee joint diseases with plans to expand to additional organ systems. The company brings together clinical, research, and regulatory expertise to advance innovative cell-based therapeutic products.

1 investor

Forema is a Japanese company working on gut microbiome analysis and lactic acid bacteria strains, including a beta microbiome analysis service for children with autism and proprietary bacterial strains. It also operates retail and other product initiatives related to these offerings.

1 investor

HikariQ Health develops innovative immunoassay methods and antibody therapeutics using proprietary Q-body technology, a fluorescence quenching-based antibody modification technique. The company targets pharmaceutical and medical applications to improve healthcare diagnostics and therapeutics globally.

1 investor

HIROTSUS Bioscience develops N-NOSE, a cancer screening test that uses nematodes to detect trace odor markers in urine samples, enabling early cancer detection. The company operates in medical diagnostics and contributes to public health through research and development.

1 investor

KORTUC develops a cancer radiotherapy (code name KRC-01) that uses hydrogen peroxide as a radiosensitizer to treat solid tumors. The company operates in the biopharmaceutical and radiation oncology space.

1 investor

LEP (株式会社LEP) develops applications based on its proprietary bioluminescent protein technology to illuminate homes and cities, pursuing agriculture, exhibition, and energy business lines. The company is based in Osaka, Japan.

1 investor

Liquid Mine develops MyRD®, a liquid biopsy-based genomic testing system that creates personalized diagnostic tests for leukemia and other cancers by analyzing individual patient genetic mutations. The company aims to advance precision medicine in oncology by making genomic testing more accessible, particularly in Japan, through collaboration with Tokyo University's Institute of Medical Science.

1 investor

Onodera develops AAV vector platforms for gene therapy research targeting neurological conditions. The company owns proprietary AAV vector patents, enabling internal development of therapeutic vectors without licensing costs from third parties.

1 investor

TearExo develops a cancer detection method that analyzes exosomes in tears, aiming for a painless, non-invasive test to assess breast cancer risk and support early detection. Spun out of Kobe University in Japan, the company targets clinical screening as an alternative to blood-based and mammography testing.

1 investor

Waqoo is a Japanese company operating in regenerative medicine and consumer brand development, focused on health and wellness products and services. It is publicly listed on the Tokyo Stock Exchange Growth Market (securities code 4937).

1 investor

ARCS Inc. develops AI and robotics automation tools that help research laboratories standardize and streamline their operations. The company works with universities and businesses to build reliable, practical products for lab environments.

1 investor

iGene develops plasma-based molecular introduction technology for cellular engineering, enabling safe and efficient delivery of DNA and proteins into cells. The company targets applications in gene therapy, regenerative medicine, agriculture, and health/beauty sectors.

1 investor

Ecologgie produces specialized insect-based feed products for reptiles, including Leobait, a leopard gecko food made from 95% freeze-dried crickets. The company develops species-specific nutritional formulas in collaboration with Japanese universities.

1 investor

Oligogen is a Japanese biotech venture focused on regenerative medicine and drug discovery, conducting novel research and development in the pharmaceutical field.

1 investor

Space Bio-Laboratories develops regenerative medicine technologies and medical devices combining biotech with robotics, including gravity control systems for cell culture and walking assistance devices. The company targets incurable diseases like stroke, spinal cord injury, and myocardial infarction through advanced biotech research and rehabilitation solutions.

1 investor

Transgenic provides mice and related genetic research products, including frozen embryos, knockout mouse libraries, plasmid DNA products, and phenotype databases for academic and research institutions conducting basic life sciences research.

1 investor

ReEir is a Japanese company founded out of regenerative medicine and wound-care expertise, working in areas such as regenerative medicine, wound surgery, and foot/podiatric care. It is led by academics and industry figures with backgrounds in plastic surgery, regenerative medicine, and medical devices.

1 investor

Renascience is a Japanese biotechnology company that develops pharmaceutical and medical projects. It presents its business model, project pipeline progress, and corporate/IR information.

1 investor

Stem Cell & Device Laboratory (SCAD) commercializes pluripotent stem cell (ES/iPS) research from Kyoto University, developing cell and tissue products that combine stem cell technology with material and device technology. Its products are aimed at drug discovery assays and regenerative medicine, serving pharmaceutical and life science companies.

1 investor

Soiken Holdings is a biotech venture originating from Osaka University's medical faculty that develops and commercializes biomarker technologies and systems for objective health assessment across food, pharmaceutical, and healthcare applications.

1 investor

Bushu Pharma is a contract development and manufacturing organization (CDMO) that provides contract manufacturing of pharmaceutical products, with GMP certifications from major countries and exports to 56 nations. It serves pharmaceutical clients as a specialist in outsourced drug manufacturing for global markets.

1 investor

Tigermed is a contract research organization (CRO) offering full-service clinical development support to the global biopharmaceutical and medical device industries, covering small molecules, biologics, vaccines, and medical devices. Founded in 2004 and publicly listed (300347.SZ / 3347.HK), it provides services including clinical monitoring, regulatory affairs, data management, and site management.

1 investor